Hang Zhang1, Shao-Liang Chen2. 1. Department of cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, Jiangsu, China. 2. Department of cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, Jiangsu, China. chmengx@126.com.
Abstract
PURPOSE OF REVIEW: Sympathetic overactivity plays an important role in the progression of pulmonary arterial hypertension (PAH). The purpose of this review is to illustrate localization of pulmonary arterial sympathetic nerves, the key steps of pulmonary artery denervation (PADN) procedure, and to highlight clinical outcomes. RECENT FINDINGS: Sympathetic nerves mostly occurred in the posterior region of the bifurcation and pulmonary trunk. Emerging preclinical data provided the potential of PADN for PAH. PADN, produced at bifurcation area, improved a profound reduction of pulmonary arterial pressure and ameliorated clinical outcomes with an exclusive ablation catheter. The application of PADN in the patients of PAH or combined pre-capillary and post-capillary PH (CpcPH) improved the hemodynamic parameters and increased 6MWD. Sympathetic overactivity aggravates PAH. PADN is a promising interventional treatment for PAH and CpcPH. Additional clinical trials are warranted to confirm the efficacy of PADN.
PURPOSE OF REVIEW: Sympathetic overactivity plays an important role in the progression of pulmonary arterial hypertension (PAH). The purpose of this review is to illustrate localization of pulmonary arterial sympathetic nerves, the key steps of pulmonary artery denervation (PADN) procedure, and to highlight clinical outcomes. RECENT FINDINGS: Sympathetic nerves mostly occurred in the posterior region of the bifurcation and pulmonary trunk. Emerging preclinical data provided the potential of PADN for PAH. PADN, produced at bifurcation area, improved a profound reduction of pulmonary arterial pressure and ameliorated clinical outcomes with an exclusive ablation catheter. The application of PADN in the patients of PAH or combined pre-capillary and post-capillary PH (CpcPH) improved the hemodynamic parameters and increased 6MWD. Sympathetic overactivity aggravates PAH. PADN is a promising interventional treatment for PAH and CpcPH. Additional clinical trials are warranted to confirm the efficacy of PADN.
Authors: Jean-Luc Vachiéry; Yochai Adir; Joan Albert Barberà; Hunter Champion; John Gerard Coghlan; Vincent Cottin; Teresa De Marco; Nazzareno Galiè; Stefano Ghio; J Simon R Gibbs; Fernando Martinez; Marc Semigran; Gerald Simonneau; Athol Wells; Werner Seeger Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Nazzareno Galiè; Paul A Corris; Adaani Frost; Reda E Girgis; John Granton; Zhi Cheng Jing; Walter Klepetko; Michael D McGoon; Vallerie V McLaughlin; Ioana R Preston; Lewis J Rubin; Julio Sandoval; Werner Seeger; Anne Keogh Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Agnieszka Ciarka; Vi Doan; Sonia Velez-Roa; Robert Naeije; Philippe van de Borne Journal: Am J Respir Crit Care Med Date: 2010-03-01 Impact factor: 21.405
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Natalia S Goncharova; Heber Ivan Condori Leandro; Aleksandr D Vakhrushev; Elena G Koshevaya; Yury A Skorik; Lubov B Mitrofanova; Lada A Murashova; Lev E Korobchenko; Elizaveta M Andreeva; Dmitry S Lebedev; Olga M Moiseeva; Evgeny N Mikhaylov Journal: BMC Pulm Med Date: 2021-12-18 Impact factor: 3.317